Effect of Talbinah food consumption on depressive symptoms among elderly individuals in long term care facilities, randomized clinical trial

This study investigated the potential effects of **Talbinah** on mood and depressive symptoms. Talbinah is described as a barley syrup cooked with milk and sweetened with honey.

The intervention was the regular consumption of Talbinah. The abstract does not specify a comparator group in the traditional sense of a placebo or an alternative food. Instead, the study used a **crossover design**, meaning participants served as their own controls, receiving both the Talbinah intervention and a control period (implied by the washout) at different times.

The primary outcomes measured were:

**Depression**: Levels of depressive symptoms.

**Stress**: Levels of perceived stress.

**Mood disturbances**: Overall negative mood states.

**Anxiety**: Levels of anxiety.

The study also performed a nutritional analysis of Talbinah to understand its composition, looking at:

Proximate food analysis (e.g., carbohydrate content).

Mineral content.

Differential amino acid analysis (e.g., tryptophan and branched-chain amino acids).

The study included a sample of **30 elderly individuals** who were identified as depressed.

**Gender breakdown**: 21 men and 9 women.

**Setting**: Participants were residents of a long-term care facility located in Seremban, Malaysia.

**Inclusion criteria**: The abstract specifies "depressed elderly subjects," implying they met certain criteria for depression, though the specific diagnostic method or severity is not detailed.

**Exclusion criteria**: Not mentioned in the abstract.

This population is specific to institutionalized elderly individuals who are already experiencing depressive symptoms, which is important context for interpreting the findings and considering self-experimentation.

The researchers used several interview-based, validated scales to assess mood, depression, stress, and anxiety. These scales are commonly used in clinical and research settings to quantify psychological states:

**Geriatric Depression Scale (GDS)**: This scale is specifically designed to screen for depression in older adults. It typically consists of a series of yes/no questions, and a higher score indicates more severe depressive symptoms. Being interview-based, it allows for clarification if needed.

**Depression Anxiety Stress Scales (DASS)**: This is a self-report questionnaire designed to measure the severity of symptoms of depression, anxiety, and stress. It comprises three subscales, each with several items. A higher score on any subscale indicates greater severity of that particular symptom. In this study, it was administered via interview.

**Profile of Mood States (POMS)**: This scale is used to assess transient, fluctuating mood states. It typically measures several mood dimensions, such as tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. A higher score generally indicates more negative mood disturbances. This was also interview-based.

Measurements were taken at four specific time points:

**Week 0**: Baseline measurement before any intervention.

**Week 3**: After the first 3-week intervention period (either Talbinah or control/washout).

**Week 4**: After a 1-week washout period.

**Week 7**: After the second 3-week intervention period (the alternative to what was received in the first period).

In addition to psychological measures, the study also conducted a **nutritional analysis of Talbinah**. This involved:

**Proximate food analysis**: To determine the major components like carbohydrates, proteins, fats, and moisture.

**Minerals content analysis**: To identify and quantify specific minerals present.

**Differential amino acid analysis**: To determine the types and amounts of amino acids, specifically noting the ratio of tryptophan to branched-chain amino acids (BCAAs). This is relevant because tryptophan is a precursor to serotonin, a neurotransmitter linked to mood.

This study employed a **3-week crossover designed, randomized clinical trial**. This is a robust study design for investigating interventions, especially in smaller populations, and it has specific implications for what the study can and cannot prove.

**How the study was run:**

1. **Randomization**: The 30 depressed elderly participants were randomly assigned to one of two sequences. In a crossover design, this typically means:

* Group A: Received Talbinah for 3 weeks, followed by a 1-week washout period, then received a control/alternative for 3 weeks.

* Group B: Received a control/alternative for 3 weeks, followed by a 1-week washout period, then received Talbinah for 3 weeks.

The abstract doesn't explicitly state what the "control/alternative" was during the non-Talbinah period, but in a crossover, participants often receive a placebo or simply their usual diet during the control phase. Given the nature of a food intervention, it's likely they either continued their usual diet or received a similar-looking/tasting but inactive food.

2. **Intervention Duration**: Each intervention period (Talbinah or control) lasted for **3 weeks**.

3. **Washout Period**: There was a **1-week washout period** between the two intervention phases. This is crucial in crossover designs to ensure that any effects from the first intervention have worn off before the second intervention begins, preventing carryover effects.

4. **Measurements**: Mood, depression, stress, and anxiety were assessed at baseline (week 0), after the first intervention period (week 3), after the washout (week 4), and after the second intervention period (week 7).

5. **Statistical Approach**: A **Wilcoxon nonparametric test** was used to analyze the data. This type of test is appropriate for comparing two related samples (like measurements from the same individuals at different times in a crossover study) when the data may not follow a normal distribution, which is common with psychological scale scores.

**Why this design matters:**

**Crossover Design**: The main advantage of a crossover design is that each participant serves as their own control. This significantly reduces variability between individuals, making it easier to detect an effect with a smaller sample size compared to a parallel-group design. It helps to control for individual differences in genetics, lifestyle, and baseline severity of depression, which are often major confounds.

**Randomization**: Randomly assigning participants to the sequence of interventions (Talbinah first vs. control first) helps to balance out any potential confounding factors that might change over time (e.g., seasonal mood changes, changes in facility routine) between the two groups. It ensures that any observed differences are more likely due to the intervention rather than pre-existing differences or time-related trends.

**What this design can and cannot prove:**

**Can prove**: With proper execution, a randomized crossover trial can provide strong evidence for a **causal relationship** between the intervention (Talbinah consumption) and the observed changes in outcomes (mood, depression, stress) *within the studied population*. The "within-subject" comparison is powerful.

**Cannot definitively prove**:

* **Generalizability**: The small sample size (30 individuals) and specific population (depressed elderly in a long-term care facility) mean that the findings may not directly apply to younger populations, healthier elderly individuals, or those living independently.

* **Long-term effects**: The 3-week intervention period is relatively short. This study cannot determine if the benefits of Talbinah would persist over longer periods or if tolerance might develop.

* **Mechanism of action**: While the nutritional analysis provides clues (high tryptophan:BCAA ratio), the study doesn't definitively prove *how* Talbinah might exert its effects. It suggests a potential pathway related to serotonin precursors but doesn't confirm it.

**Major methodological weaknesses:**

**Lack of Blinding**: The abstract does not mention blinding. For a food intervention, it is extremely challenging, if not impossible, to blind participants (they would know if they are eating Talbinah). It is also difficult to blind the interviewers who are administering the scales. This is a significant weakness because participants' expectations (the **placebo effect**) or